rttnews.com
Cure8 news brief
Why This Matters
Perianal fistulas are a common, disabling complication of Crohn’s disease. A medication that provides durable fistula remission through 48 weeks could change treatment options for people with Crohn’s and perianal disease.
The report focuses on Phase 3 trial outcomes for TREMFYA (guselkumab), an IL-23 inhibitor already used in other inflammatory diseases.
Who Should Pay Attention
Adults with Crohn’s disease, especially those with perianal fistulas; gastroenterologists and colorectal surgeons treating fistulizing disease; clinical researchers in IBD and IL-23–targeted therapies.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
Johnson & Johnson (Janssen) reported positive 48-week Phase 3 (FUZION) results for TREMFYA (guselkumab) in adults with Crohn’s disease and perianal fistula.
The company states combined fistula remission (clinical + radiologic) was maintained or improved through Week 48 versus earlier timepoints, with quoted Week 24 to Week 48 increases in the 100 mg group (28% to 35%). Safety through Week 48 was described as consistent with the known profile.
This summary is based on the RTT News article reporting company-released trial results.
Keep In Mind
This article is a news report summarizing company-announced Phase 3 data (FUZION). RTT News relays J&J/Janssen’s statements; the full peer-reviewed publication or regulatory filings were not provided in the article.
Reported percentages come from the company’s press information; independent peer-reviewed confirmation and regulatory review are needed before changing clinical practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationrttnews.com
AuthorsRTTNews Staff Writer
Indexed viaBing News
Source typeWeb article
PublishedOct 18, 2026, 4:44 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key ...
Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...
Subcutaneous Guselkumab Proves Efficacious for IBD in Two Studies: ASTRO and GRAVITI
These are phase 3 results showing subcutaneous guselkumab helped more people reach clinical and endoscopic goals than placebo in moderate-to-severe UC and Crohn’s disease; a fully subcutaneous option could offer more...